Companies › Immunome
5 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AL102 Gamma secretase inhibitor targeting Notch signaling | NOTCH1, NOTCH2, NOTCH3 | Phase 2 | Desmoid | Dec 2026 |
| Varegacestat Presenilin-1 (PS1) inhibitor; gamma-secretase inhibitor | PSEN1 | Phase 1 | Healthy | May 2027 |
| IM-1021 antibody-drug conjugate | – | Phase 1 | Solid Malignancies | May 2028 |
| IM-1617 antibody-drug conjugate | – | Phase 1 | Colorectal Cancer | Jan 2029 |
| 177Lu-IM-3050 FAP-directed radiopharmaceutical | FAP | Phase 1 | Solid Malignancies | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04871282 | AL102 | Phase 2 | Desmoid | Oncology | Dec 2026 |
| NCT07610005 | Varegacestat | Phase 1 | Healthy | Other | May 2027 |
| NCT06823167 | IM-1021 | Phase 1 | Solid Malignancies | Oncology | May 2028 |
| NCT07578571 | IM-1617 | Phase 1 | Colorectal Cancer | Oncology | Jan 2029 |
| NCT07505771 | 177Lu-IM-3050 | Phase 1 | Solid Malignancies | Oncology | Dec 2029 |
Cash and short-term investments of $462m on 2026-09-30; operating cash outflow about $243m a year; runway about 23 months at that burn, to Aug 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Cogent Biosciences ORIC Pharmaceuticals Chengdu New Radiomedicine Technology ArriVent BioPharma Olema Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.